site map  

 Coagulation Factor IX

  PRODUCTS ORDERING SERVICES ABOUT US FAQ/TECH NOTES CONTACT

Human Proteins   Bovine Proteins   Mouse Proteins   Other Species  Inhibitors

   Substrates   Antibodies   Sample Collection Tubes  Assay Kits  Deficient Plasmas  Pricing

 

 


Haematologic Technologies, Inc.

57 River Road

Essex Junction, VT USA

Tel: 802.878.1777

Fax: 802.878.1776

Email: hti@haemtech.com

HOME PAGE

DOMAIN STRUCTURE OF FACTOR IX The domain structure of factor IX is represented, where: GLA=region containing γ-carboxyglutamic acid residues, EGF=region containing sequences homologous to human epidermal growth factor, AP=activation peptide released upon conversion of the zymogen to the active serine protease, and CATALYTIC DOMAIN=region containing the serine protease catalytic triad. Arrows indicate the sites which are proteolytically cleaved by factor XIa during activation of the zymogen, with arrow A being cleaved first.

The zymogen factor IX is a single chain vitamin K-dependent glycoprotein which is synthesized in the liver (1-3). The domain structure of factor IX is similar to that of the other vitamin K dependent coagulation factors. The NH2-terminal region contains 12 γ-carboxyglutamic acid (gla) residues which facilitate the calcium dependent binding of factor IX to negatively charged phospholipid surfaces. Two domains which are homologous to epidermal growth factor (EGF) span the region between the NH2-terminal gla domain and the activation peptide (Ala-146 to Arg-180). 
Factor IX is activated by either factor XIa or the factor VIIa/tissue factor/phospholipid complex. Cleavage at site A (see figure) yields the intermediate IXa which is subsequently converted to the fully active form IXa
β by cleavage at site B. The NH2-terminal light chain (GLA and EGF domains) remains covalently attached to the COOH-terminal heavy chain by a disulfide bond. The serine protease catalytic triad (Ser-365, His 221, Asp-269) is located in the heavy chain. Factor IXaβ is the catalytic component of the "intrinsic factor Xase complex" (factor VIIIa/IXa/Ca2+/phospholipid) which proteolytically activates factor X to factor Xa.


Human factor IX is prepared from fresh frozen plasma by a combination of conventional procedures (4) and immunoaffinity chromatography (5). Bovine factor IX is prepared from fresh citrated bovine plasma by a modification of the method described by Fujikawa et al. (6). The purified proteins are supplied in 50% (vol/vol) glycerol/H2O and should be stored at -20oC. Purity is determined by SDS-PAGE analysis and activity is measured using a factor IX clotting assay. 

 

Properties of Factor IX

Localization: Plasma
Plasma concentration: 4-5 ug/ml (human) (1)
Mode of action: Zymogen; precursor to the serine protease factor IXa
Molecular weight: 55,000 (human) (8)
55,400 (bovine) (6)
Extinction coefficient:
E
1 %
1 c m, 280 nm
= 13.2 (human)(7)
= 12.0 (bovine) (6)
Isoelectric point: 4.2-4.5 (human) (7)
3.7 (bovine) (6)
Structure: single chain, NH2-terminal gla-domain, two EGF domains
Percent carbohydrate: 17% (human) (7)
26% (bovine) (6)
Post-translational modifications: one β-hydroxyaspartate (9), twelve gla residues (7)

Catalog Number

Description

HCIX-0040

Human Factor IX

BCIX-1040

Bovine Factor IX

MCIX-5040

Mouse Factor IX

PRICING

INQUIRE ABOUT THIS PRODUCT

References 
1. Thompson, A.R., Blood, 67, 565 (1986). 
2. Hedner, U., et al., In Hemostasis and Thrombosis, 2nd edition, ed. R.W. Colman, J. Hirsh, V.J. Marder, E.W. 3. Salzman, pp. 39-47. J.P. Lippincott Co, Philadelphia, 1987. 
4. Fujikawa, K., Davie, EW., Methods in Enzymology, 45, 74 (1976). 
5. Bajaj, S.P., et al., Prep. Biochem., 11, 397 (1981). 
6. Jenny, R.J., et al., Prep. Biochem., 16, 227 (1986). 
7. Fujikawa, K., et al., Biochemistry, 12, 4938 (1973). 
8. Discipio, R.G., et al., Biochemistry, 16, 698 (1977). 
9. Osterud, B., et al., J. Biol. Chem., 253, 5946 (1978). 
10.McMullen, B.A., et al., BBRC, 115, 8 (1983). 

 

 Please inquire about products not listed.  We can also custom purify proteins from other species. 

© 2004 Haematologic Technologies, Inc. All Rights Reserved